JBIO — Defiance Nasdaq Junior Biotechnology ETF
Data updated: 2021-11-29
JBIO — Defiance Nasdaq Junior Biotechnology ETF. Global (incl. US) Growth Health Care Equity · $7.25M AUM. Holdings, fees, performance and SEC filings.
JBIO Fund Overview
JBIO — Defiance Nasdaq Junior Biotechnology ETF is a US ETF managed by ETF Series Solutions, categorised as Global (incl. US) Growth Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: ETF Series Solutions
- Category: Global (incl. US) Growth Health Care Equity
- Assets under management: $7.25M
- 1-year return: 12.5%
- Ticker: JBIO
- SEC CIK: 0001540305
- SEC series ID: S000064808
- Share class ID: C000209830
JBIO Investment Objective and Strategy
Defiance Nasdaq Junior Biotechnology ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by ETF Series Solutions.
Investment objective
The Defiance Nasdaq Junior Biotechnology ETF (the Fund) seeks to track the total return performance, before fees and expenses, of the NASDAQ Junior Biotechnology Index (the Index).
Principal investment strategy
The Fund uses a passive management (or indexing) approach to track the total return performance, before fees and expenses, of the Index. NASDAQ Junior Biotechnology Index The Index is a rules-based index that consists of a portfolio of the stock of U.S.-listed small capitalization (junior) companies screened from the universe of the NASDAQ Biotechnology Index (collectively, Junior Biotech Companies), which includes companies classified as biotechnology or pharmaceutical according to the Industry Classification Benchmark. To be eligible for inclusion in the Index, a security must meet investibility requirements, including a minimum market capitalization of $200 million and a market capitalization that is less than $5 billion as of the reference date of the annual evaluation (as described below).
The Index is reconstituted ( i.e. , constituents are removed or added) annually after the close of trading on the third Friday in December and rebalanced ( i.e. , weights are reset, but no constituents are removed or added) on a quarterly basis on the third Friday in March, June, September and December. At the time of each rebalance and reconstitution of the Index, each constituent is market capitalization-weighted, subject to a maximum individual weight of 8% for each of the five most heavily weighted constituents and 4% for all other constituents. The Index was established in 2020 and is owned by Nasdaq Global Indexes (the Index Provider). The Index Provider may, from time to time, exercise reasonable discretion with respect to the composition or weighting of the Index as it deems appropriate to ensure Index integrity.
The Funds Investment Strategy Under normal circumstances, the Fund invests at least 80% of its net assets (plus borrowings for investment purposes) in junior biotechnology companies. For purposes of the foregoing policy, the Fund defines junior companies to mean companies with a market capitalization of less than US$5 billion as of the most recent rebalance or reconstitution of the Index. Additionally, the Fund defines biotechnology companies to be those that were in the Biotechnology Subsector according to the Industry Classification Benchmark as of the most recent rebalance or reconstitution of the Index. The foregoing policy may be changed without shareholder approval upon 60 days written notice to shareholders. The Fund will generally use a replication strategy to achieve its investment objective, meaning the Fund will generally invest in all of the component securities of the Index in the same approximate proportions as in the Index.
However, the Fund may use a representative sampling strategy, meaning it may invest in a sample of the securities in the Index whose risk, return, and other characteristics closely resemble the risk, return, and other characteristics of the Index as a whole, when the Funds sub-adviser believes it is in the best interests of the Fund ( e.g. , when replicating the Index involves practical difficulties or substantial costs, an Index constituent becomes temporarily illiquid, unavailable, or less liquid, or as a result of legal restrictions or limitations that apply to the Fund but not to the Index). The Fund generally may invest in securities or other investments not included in the Index, but which the Funds sub-adviser believes will help the Fund track the Index. For example, the Fund may invest in securities that are not components of the Index to reflect various corporate actions and other changes to the Index (such as reconstitutions, additions, and deletions).
To the extent the Index concentrates ( i.e. , holds more than 25% of its total assets) in the securities of a particular industry or group of related industries, the Fund will concentrate its investments to approximately the same extent as the Index. As of March 31, 2021, the Index was concentrated in Junior Biotech Companies. The Fund is considered to be non-diversified, which means that it may invest more of its assets in the securities of a single issuer or a smaller number of issuers than if it were a diversified fund.
JBIO Performance
Total returns for JBIO (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| 1 year | 12.5% |
JBIO Risk Information
Risk metrics for JBIO, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 26.9%
JBIO Costs and Fees
JBIO costs about $45 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.45%
- Gross expense ratio: 0.45%
- Portfolio turnover: 66%
- Brokerage commissions: 7.02 bps of average net assets (SEC N-CEN)
JBIO Cashflows
Over the 12 months to 2021-09, Defiance Nasdaq Junior Biotechnology ETF had net inflows of $8.00M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2021-09 | $0 |
| 2021-08 | $0 |
| 2021-07 | $0 |
| 2021-06 | $0 |
| 2021-05 | $0 |
| 2021-04 | $0 |
JBIO Debt Constituents
No individual debt constituents are reported in Defiance Nasdaq Junior Biotechnology ETF's latest SEC N-PORT filing.
JBIO Prospectus and SEC Filings
Official Defiance Nasdaq Junior Biotechnology ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2021-04-27
- Prospectus (485BPOS) — filed 2020-05-14
- Prospectus supplement (497) — filed 2020-07-31
- Portfolio holdings (N-PORT) — filed 2021-11-29
- Portfolio holdings (N-PORT) — filed 2021-08-25
- Portfolio holdings (N-PORT) — filed 2021-05-27
- Annual census (N-CEN) — filed 2021-03-16
Related Funds
Related funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.